Ra has been shown to not only have a palliative effect but also a survival prolonging effect in metastatic, castration-resistant prostate cancer with bone metastases. This article reviews the different radionuclide-based approaches for targeting bone metastases, with an emphasis on 223 Ra, and key elements of the underlying radiobiology of these that will impact their clinical effectiveness.Consideration is given to the remaining unknowns of both the basic radiobiological and applied clinical effects of 223 Ra as targets for future research.A significant burden is imposed on patients with cancer by osseous metastases; they are common in many forms of malignancy and are often highly symptomatic. In an early autopsy series of 1000 patients dying from disseminated malignancy of various primary sites, Abrams et al 1 found bone metastases present in 27.2% of their series. Metastases have biologically defined tropisms related to their site of origin. Although the biochemical determinants of these tropisms remain poorly understood, their effects are clear in the clinic and mean that certain sites of cancers have a particular preponderance for forming bone metastases. Autopsy data adapted by Coleman 2 show that 73% of patients dying of breast cancer, 68% of patients dying of prostate cancer and 36% of patients dying of lung cancer have bone metastases present at post-mortem. Of those patients with osseous metastases, a significant proportion goes on to develop skeletal-related events (SREs) in relation to their metastases. The precise definition of SREs differs between trials, but they generally refer to any of the following four clinical outcomes: the need for external beam radiotherapy (EBRT) for bone pain, development of malignant spinal cord compression, pathological fracture (symptomatic or asymptomatic) or the need for orthopaedic intervention to bone metastasis. In the context of a lifelimiting illness, any of the above is obviously of huge detriment to a patient's well-being on a number of fronts; pain by its very nature, time spent attending hospital, immobility associated with fracture/surgery etc. In their review of Phase 3 randomized trials of bone-modifying agents, Poon et al 3 show that in the placebo arms of 11 such trials, the percentage of patients with bone metastases experiencing SREs ranged from 23.47% to 67.2%. Thus bone metastases are a common finding in advanced malignancy and within the cohort of patients experiencing them; SREs are a common outcome, with obvious detriment to the quality of life of the patients affected.EBRT is a proven and well-established means of managing pain associated with bone metastases. In their systematic review of studies examining the palliative benefit of EBRT for bone metastases, Chow et al 4 found overall response rates, with regard to pain, of 58% for single fraction and 59% for multiple fraction treatments. The same authors found complete pain response rates of 23% in single fraction and of 24% in multiple fraction treatments. A large determinant of the degree...